Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27763193 | 0.86 | ALDH1A1 (0.52) | KMT2AALDH1A1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL12931078 | 0.85 | ALDH1A1 (0.50) | KMT2AALDH1A1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL1424440 | 0.80 | ALDH1A1 (0.67) | KMT2AALDH1A1LMNAGPR35HSD17B10 | |
| SCHEMBL27804372 | 0.80 | ALDH1A1 (0.44) | KMT2AALDH1A1LMNAGPR35MAPT | |
| SCHEMBL28030677 | 0.77 | KMT2A (0.61) | KMT2AALDH1A1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL1789120 | 0.76 | KMT2A (0.75) | KMT2AALDH1A1LMNASMN1; SMN2CYP3A4 | |
| Aklomide SCHEMBL328368 | 0.76 | KMT2A (1.00) | KMT2AALDH1A1SMN1; SMN2CYP3A4CASP1 | |
| Aklomide SCHEMBL29637033 | 0.76 | KMT2A (1.00) | KMT2AALDH1A1SMN1; SMN2CYP3A4CASP1 | |
| SCHEMBL28515247 | 0.75 | ALDH1A1 (0.62) | KMT2AALDH1A1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL27710570 | 0.75 | KMT2A (0.55) | KMT2AALDH1A1LMNASMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121164-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-02-19 | — | — | EP | disclosed |
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-06 | — | — | US | disclosed |
| US-10457638-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-29 | — | — | US | disclosed |
| EP-2997011-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-08-29 | — | — | EP | disclosed |
| US-20180141905-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-24 | — | — | US | disclosed |
| US-9884818-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-06 | — | — | US | disclosed |
| EP-3121164-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2017-01-25 | — | — | EP | disclosed |
| US-20160115125-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-28 | — | — | US | disclosed |
| EP-2997011-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184350-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-11-20 | — | — | WO | disclosed |
| CN-102341395-B | 3H-imidazo [4,5-c ] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INT | 2014-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141905-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | KMT2A 1220/4885ALDH1A1 3351/4885LMNA 2665/4885 |
| US-10457638-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | RB1, XDH, HBS1L | KMT2A 1220/4885ALDH1A1 3351/4885LMNA 2665/4885 |
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | KMT2A 1220/4885ALDH1A1 3351/4885LMNA 2665/4885 |
| US-20160115125-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | KMT2A 1220/4885ALDH1A1 3351/4885LMNA 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.